This is a phase 1 study, designed to evaluate the safety and effectiveness of the WRAPSODY Stent Graft for the treatment of venous outflow circuit obstructions in the veins of the arm or thoracic central veins of subjects who receive chronic dialysis treatment for end stage renal disease.
The study will consist of a screening period in which subject eligibility will be determined. Approximately 50 subjects meeting the study entry criteria will be enrolled. Placement of the WRAPSODY stent graft will follow the procedure. Post study procedure subjects will have planned follow-up visits at 30 days, 3, 6 and 12months, and additional visits as referred by the subject's dialysis facility. The primary study safety endpoint will be the proportion of subjects without any localized or systemic safety events through 30 days that affect the access or venous outflow circuit and resulted in surgery, hospitalization, or death. Subjects will continue to be followed up to 12 months for supplementary information.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
46
The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
G. Gennimatas General Hospital of Athens
Athens, Greece
Queen Elizabeth University Hospital
Glasgow, United Kingdom
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Number of Participants Without Any Localized or Systemic Safety Events Through 30 Days
The total number of subjects without any localized or systemic safety events through 30 days that affect the access or venous outflow circuit and resulted in surgery, hospitalization, or death
Time frame: 30 days
Number of Participants With Target Lesion Primary Patency at 30 Days
The total number of subjects with Target Lesion Primary Patency at 30 days
Time frame: 30 days
Number of Participants With Target Lesion Primary Patency at 3 Months
The total number of subjects with Target Lesion Primary Patency at 3 months
Time frame: 3 months
Number of Participants With Target Lesion Primary Patency at 6 Months
The total number of subjects with Target Lesion Primary Patency at 6 months
Time frame: 6 months
Number of Participants With Target Lesion Primary Patency at 12 Months
The total number of subjects with Target Lesion Primary Patency at 12 months
Time frame: 12 months
Number of Participants With Assisted Target Lesion Primary Patency at 30 Days
The total number of subjects with Assisted Primary Patency of the Target Lesion at 30 days
Time frame: 30 days
Number of Participants With Assisted Target Lesion Primary Patency at 3 Months
The total number of subjects with Assisted Primary Patency of the Target Lesion at 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 3 months
Number of Participants With Assisted Target Lesion Primary Patency at 6 Months
The total number of subjects with Assisted Primary Patency of the Target Lesion at 6 months
Time frame: 6 months
Number of Participants With Assisted Target Lesion Primary Patency at 12 Months
The total number of subjects with Assisted Primary Patency of the Target Lesion at 12 months
Time frame: 12 months
Number of Participants With Access Circuit Primary Patency at 30 Days
The total number of subjects with Access Circuit Primary Patency at 30 days
Time frame: 30 days
Number of Participants With Access Circuit Primary Patency at 3 Months
The total number of subjects with Access Circuit Primary Patency at 3 months
Time frame: 3 months
Number of Participants With Access Circuit Primary Patency at 6 Months
The total number of subjects with Access Circuit Primary Patency at 6 months
Time frame: 6 months
Number of Participants With Access Circuit Primary Patency at 12 Months
The total number of subjects with Access Circuit Primary Patency at 12 months
Time frame: 12 months
Number of Participants With Assisted Access Circuit Primary Patency at 30 Days
The total number of subjects with Assisted Access Circuit Primary Patency at 30 days
Time frame: 30 days
Number of Participants With Assisted Access Circuit Primary Patency at 3 Months
The total number of subjects with Assisted Access Circuit Primary Patency at 3 months
Time frame: 3 months
Number of Participants With Assisted Access Circuit Primary Patency at 6 Months
The total number of subjects with Assisted Access Circuit Primary Patency at 6 months
Time frame: 6 months
Number of Participants With Assisted Access Circuit Primary Patency at 12 Months
The total number of subjects with Assisted Access Circuit Primary Patency at 12 months
Time frame: 12 months
Number of Participants With Clinical Success
The resumption of successful dialysis through existing access for at least one session following the initial study procedure
Time frame: 30 days
Number of Participants With Anatomic Success
Less than 30% residual stenosis immediately following the study procedure
Time frame: Immediately following the study procedure
Number of Participants With Procedural Success
The achievement of both clinical and anatomic success
Time frame: 30 days